BioHouston

Premier Underwriter Table

Wed, 23 Jul 2008 20:31:56 GMT

Premier Underwriter Table
Start Date: 11-Sep-48 11:30 AM
End Time: 11-Sep-48 1:30 PM
Location: Crystal Ballroom at the Rice Hotel, Houston, TX 77002
Speaker:

Event Details:

2008 Annual Luncheon

Bringing Research to Life

Dr. Elsa Murano

Texas A&M University

September 11, 2008

11:30 AM - 1:30 PM

The Crystal Ballroom at The Rice

909 Texas Ave.

Houston, TX 77002

The upcoming BioHouston annual luncheon, Bringing Research to Life, will feature the new Texas A&M President, Dr. Elsa Murano, as our speaker. Research, particularly in the rapidly expanding life sciences, is the cornerstone in Texas A&M’s quest to become a top-10 public institution by 2020. The impact of this aggressive initiative by the Aggies is far-reaching, as well as critical in expanding the intellectual capital of the state.

Dr. Murano began her professorial career in 1990 as an Assistant Professor in the Department of Microbiology, Immunology and Preventative Medicine at Iowa State, the position she held prior to joining the Texas A&M faculty. She received a bachelor's degree in biological sciences from Florida International University, and earned both a master's degree in anaerobic microbiology and a doctorate in food science and technology from Virginia Tech. Dr. Murano is the first woman and first Hispanic-American to lead the oldest public institution of higher learning in Texas—now one of the largest teaching and research universities in the nation.

Proceeds from the luncheon will benefit BioHouston’s initiatives to build the region’s biotech industry, creating medical breakthroughs that will transform health care, improve lives, and create economic growth.

For questions regarding sponsorship or event information, contact Keisha Curtis at 713-979-9212 or keisha.curtis@biohouston.org

Crystal Ballroom at the Rice Hotel

909 Texas Ave.

Houston, TX US 77002

Benefactor Table

Wed, 23 Jul 2008 20:33:58 GMT

Benefactor Table
Start Date: 11-Sep-48 11:30 AM
End Time: 11-Sep-48 1:30 PM
Location: Crystal Ballroom at the Rice Hotel, Houston, TX 77002
Speaker:

Event Details:

2008 Annual Luncheon

Bringing Research to Life

Dr. Elsa Murano

Texas A&M University

September 11, 2008

11:30 AM - 1:30 PM

The Crystal Ballroom at The Rice

909 Texas Ave.

Houston, TX 77002

For questions regarding sponsorship or event information, contact Keisha Curtis at 713-979-9212 or keisha.curtis@biohouston.org

Crystal Ballroom at the Rice Hotel

909 Texas Ave.

Houston, TX US 77002

Major Underwriter Table

Wed, 23 Jul 2008 20:38:35 GMT

Major Underwriter Table
Start Date: 11-Sep-48 11:30 AM
End Time: 11-Sep-48 1:30 PM
Location: Crystal Ballroom at the Rice Hotel, Houston, TX 77002
Speaker:

Event Details:

2008 Annual Luncheon

Bringing Research to Life

Dr. Elsa Murano

Texas A&M University

September 11, 2008

11:30 AM - 1:30 PM

The Crystal Ballroom at The Rice

909 Texas Ave.

Houston, TX 77002

For questions regarding sponsorship or event information, contact Keisha Curtis at 713-979-9212 or keisha.curtis@biohouston.org

Crystal Ballroom at the Rice Hotel

909 Texas Ave.

Houston, TX US 77002

Individual Benefactor

Wed, 23 Jul 2008 20:46:15 GMT

Individual Benefactor
Start Date: 11-Sep-48 11:30 AM
End Time: 11-Sep-48 1:30 PM
Location: Crystal Ballroom at the Rice Hotel, Houston, TX 77002
Speaker:

Event Details:

2008 Annual Luncheon

Bringing Research to Life

Dr. Elsa Murano

Texas A&M University

September 11, 2008

11:30 AM - 1:30 PM

The Crystal Ballroom at The Rice

909 Texas Ave.

Houston, TX 77002

For questions regarding sponsorship or event information, contact Keisha Curtis at 713-979-9212 or keisha.curtis@biohouston.org

Crystal Ballroom at the Rice Hotel

909 Texas Ave.

Houston, TX US 77002

Individual Underwriter

Wed, 23 Jul 2008 20:40:54 GMT

Individual Underwriter
Start Date: 11-Sep-48 11:30 AM
End Time: 11-Sep-48 1:30 PM
Location: Crystal Ballroom at the Rice Hotel, Houston, TX 77002
Speaker:

Event Details:

2008 Annual Luncheon

Bringing Research to Life

Dr. Elsa Murano

Texas A&M University

September 11, 2008

11:30 AM - 1:30 PM

The Crystal Ballroom at The Rice

909 Texas Ave.

Houston, TX 77002

For questions regarding sponsorship or event information, contact Keisha Curtis at 713-979-9212 or keisha.curtis@biohouston.org

Crystal Ballroom at the Rice Hotel

909 Texas Ave.

Houston, TX US 77002

Individual Sponsor

Wed, 23 Jul 2008 20:47:59 GMT

Individual Sponsor
Start Date: 11-Sep-48 11:30 AM
End Time: 11-Sep-48 1:30 PM
Location: Crystal Ballroom at the Rice Hotel, Houston, TX 77002
Speaker:

Event Details:

2008 Annual Luncheon

Bringing Research to Life

Dr. Elsa Murano

Texas A&M University

September 11, 2008

11:30 AM - 1:30 PM

The Crystal Ballroom at The Rice

909 Texas Ave.

Houston, TX 77002

For questions regarding sponsorship or event information, contact Keisha Curtis at 713-979-9212 or keisha.curtis@biohouston.org

Crystal Ballroom at the Rice Hotel

909 Texas Ave.

Houston, TX US 77002

BIO-Europe 2008

Tue, 13 May 2008 21:50:23 GMT

BIO-Europe 2008
Start Date: 17-Nov-08 0:00 AM
End Time: 19-Nov-08 0:00 AM
Location: m:con Congress Center Rosengarten
Speaker:

Event Details:

BIO-Europe brings together international decision-makers from the biotechnology, pharmaceutical and financial sectors, offering networking opportunities, workshop participation, and private, pre-scheduled one-to-one meetings. Investment and collaboration opportunities developed in prior BIO- Europe conferences have produced many highly successful business partnerships.

Highlights include:

State-of-the-art partnering software that enables participants to select the most suitable potential partners. The system - industry-specific, web based and interactive - is uniquely suited for the needs of biotech and pharma companies.
Selected biotechnology, mid-sized & big pharmaceutical companies present their products/technologies and corporate missions in 15 minute presentations.
High level faculty on panels and workshops, in which industry experts provide updated analyses and share their experience with the audience.
An international exhibition of major bio-industry leaders who showcase their products, services and technologies.

For more information and to register, click here.

m:con Congress Center Rosengarten

Rosengartenplatz 2

Mannheim Germany 68161

Texas Life Science Conference

Tue, 04 Mar 2008 19:54:07 GMT

Texas Life Science Conference
Start Date: 5-Nov-08 0:00 AM
End Time: 7-Nov-08 12:00 PM
Location: The Brown Foundation Institute of Molecular Medicine, Houston, TX 77030
Speaker:

Event Details:

The Texas Life Science Conference is Texas' premier venture conference, the most comprehensive showcase of cutting edge research and innovative entrepreneurs in the state. The 2008 conference will build on the 2007 format, highlights of which include:

50 companies and technologies presented to over 315 conference attendees ranging from industry luminaries and key venture capitalists to leaders of emerging biotech companies, research scientists, and entrepreneurs

Over $6 billion in current funds represented by attending investors

The Michael E. DeBakey Life Science Award for the Texas undiscovered life science company with the highest potential to commercialize an important product

You won't want to miss the best of what's emerging out of Texas...mark your calendars and join us for the 2008 event!

For more information, please contact Keisha Curtis at 713-979-9212.

We are pleased to announce our partnership with Texas Healthcare and Bioscience Institute (THBI). This collaboration ensures representation from the most promising life science companies from across the state.

The Brown Foundation Institute of Molecular Medicine

1825 Pressler Street

Houston, TX 77030

16th Annual BioPartnering Europe

Fri, 25 Jan 2008 18:05:42 GMT

16th Annual BioPartnering Europe
Start Date: 12-Oct-08 0:00 AM
End Time: 14-Oct-08 12:30 PM
Location: Queen Elizabeth II Conference Centre
Speaker:

Event Details:

BioPartnering Europe (BPE) was first held in London in 1993 as a partnership between the U.S. Commercial Service and Technology Vision Group LLC to bring about closer ties between American and European biotechnology companies. From the beginning, BPE has attracted the support of leading pharmaceutical, biotechnology, financial and service companies who have all contributed to making this one of the leading independent partnering events in the world. BPE has a high rate of sponsor retention, which signals its prominent role in the annual conference calendar for many industry leaders.

More details to come soon.

For registration and more information, click here.

Queen Elizabeth II Conference Centre

Broad Sanctuary, Westminster

London United Kingdom

BioContact Qubec 2008

Tue, 04 Mar 2008 20:07:46 GMT

BioContact Québec 2008
Start Date: 1-Oct-08 0:00 AM
End Time: 3-Oct-08 12:00 PM
Location: Château Frontenac, Quebec, Quebec G1R4P5
Speaker:

Event Details:

BioContact Québec 2008 will make available private meeting rooms for one-on-one sessions. These meetings will be offered in consecutive 30-minute periods. Senior representatives from presenting biopharmaceutical companies and our strategic partners will be on hand for biopartnering sessions.

This year’s event will offer four presentation sessions (Block I - IV). More than 150 biopharmaceutical companies, coming from Canada, the United States, Asia and Europe, will be presenting in different sectors of activities (diagnostics, therapeutics and services) and disciplines such as:

Cancer
Cardiology
Drug Delivery Systems
Endocrinology / Metabolism
Genomics / Proteomics
Immunology / Infectiology
Medical Technologies
Neurobiology
Services
Virology
Others

For more information and to register, click here.

Château Frontenac

1 rue des Carrieres

Quebec, Quebec Canada G1R4P5

President Bush, Congressional Leaders Award DeBakey Nation's Highest Civilian Honor

noemail@biohouston.org — Wed, 23 Apr 2008 15:30:00 GMT

April 23, 2008 -- It's all gold for Dr. Michael E. DeBakey.

In the grand Rotunda of the U.S. Capitol, surrounded by Congressional leaders, friends and colleagues, Baylor College of Medicine's renowned leader humbly accepted the Congressional Gold Medal, the nation's highest civilian honor, from President George W. Bush and the leaders of Congress. See CSpan coverage.

"My first thought of course is to express my deep-seated and humblest sense of gratitude for this high honor you have afforded me," DeBakey said during the ceremony. "Since receiving this award, my cup runneth over."
The medal, designed by sculptor-engraver Don Everhart of the U.S. Mint, was commissioned after both the U.S. Senate and U.S. House of Representatives approved legislation supporting the award for the pioneering heart surgeon. President Bush signed the final bill in October of last year.

Throughout U.S. history, the Congressional Gold Medal has been awarded sparingly, in recognition of the tremendous accomplishments that it takes to earn this high honor, President Bush said at the ceremony on Wednesday. "Dr. DeBakey has an impressive resume, but his truest legacy is not inscribed on a medal or etched into stone. It is written on the human heart. His legacy is the unlost hours with family and friends who are still with us because of his healing touch. His legacy is grandparents who lived to see their grandchildren. His legacy is holding the fragile and sacred gift of human life in his hands -- and returning it unbroken."

Speaker of the House Nancy Pelosi and Senate Majority Leader Harry Reid joined the President in presenting the award to DeBakey.

U.S. Senator Kay Bailey Hutchison and U.S. Rep. Al Green led efforts to pass the legislation approving the Medal. Both leaders spoke at the event.

"This is the highest award that Congress can bestow on a civilian. With this honor, Dr. DeBakey joins the company of George Washington, Winston Churchill and Thomas Edison," Hutchison said. "When he was told about this prestigious honor, Dr. DeBakey said, ‘My pride as a citizen of the United States of America is overflowing.' Today, our pride is in you Dr. DeBakey, as we recognize your extraordinary impact on America and the world."

"On September 7 of this year, his life will measure and span 100 years. However, the most meaningful measure of life is not how long one lives, but rather what one does with the time that God gives. Dr. DeBakey, your living has made it possible for others to have better lives," said Green. "If we did not have the Congressional Gold Medal, we would have to create it for the honorable Dr. Michael E. DeBakey."

A large number of DeBakey's Houston friends and colleagues attended the ceremony, led by BCM President and CEO Dr. Peter G. Traber. Chancellor Emeritus William T. Butler, Chancellor Bobby R. Alford and a number of BCM faculty leaders were on hand to see DeBakey receive the award, as were many Texas Medical Center leaders.

DeBakey has said the permanent home of the Congressional Gold Medal will be in the DeBakey Library and Museum at BCM.

23-Apr-08 10:30 AM

SBIR/STTR Reauthorization Act Approved

Thu, 17 Apr 2008 17:00:00 GMT

The US House of Representatives passed HR 5819, the "SBIR/STTR Reauthorization Act," by a vote of 369 yeas to 43 nays. This bill reauthorizes the Small Business Innovation Research Grant program and modifies the eligibility rules affecting venture capital backed companies for receiving SBIR grants. It will increase access to critical, early-stage sources of funding for small businesses, including small biotechnology firms, thus facilitating economic growth, job creations, new breakthrough therapies for patients in need, and American economic competitiveness in the global economy.

The Bill which was introduced by Congresswoman Nydia M. Velázquez (D - NY), contains a provision that changes the definition of a small business from the current definition of "independently owned" to include businesses owned up to 49.9 percent by a venture capital firm. Title II of the act amends Sec. 9 (e) of the Small Business Act, which is specific to the SBIR program.

According to Genomeweb.com the bill would, "reauthorize the programs through 2010 and would give Congress time to examine how the programs are working. The bill also would increase funding levels, raising Phase I awards from $100,000 to $300,000 and Phase II awards from $750,000 to $2.2 million, to reflect the rising costs of high-tech research. The authorization also increases the SBIR program's flexibility by allowing cross-agency awards, letting applicants apply directly for Phase II funding, and loosening eligibility for awards to include small businesses that are backed by venture capital funding. The bill expands the requirements for databases of recipients and it requires interoperability and accessibility between databases in order to allow for better congressional oversight."

17-Apr-08 12:00 PM

Texas Makes Top 5 Biotech Regions

Fri, 22 Feb 2008 22:00:00 GMT

HOUSTON, February 22, 2008 - Texas has been named for the first time as one of the Top 5 regions in the world for biotechnology economic development efforts in the annual rankings compiled by the newsletter FierceBiotech.

The primary reason cited for Texas' rise in the rankings is ratification of the state's $3 billion in funding for cancer research by Texas voters last Fall. The bond initiative will allow the Texas legislature to authorize up to $3 billion in bonds over ten years on behalf of a newly formed Cancer Research and Prevention Institute.

"We believe that this honor is recognition of the progress that has been made over the last 5 years in the growth of a thriving life science industry in Houston," said BioHouston President and CEO Jacqueline Northcut. The Houston region now has over 140 life science companies, double the number that existed here in 2003. To see the complete article, click on the following links: Article 1 Article 2

22-Feb-08 4:00 PM

Introgen Announces ADVEXIN(R) Shows Statistically Significant Six-Month and Overall Survival Benefit as Compared to Methotrexate in Prospectively Defined Biomarker Patient Population

noemail@biohouston.org — Wed, 23 Jul 2008 05:00:00 GMT

July 23, 2008 -- Introgen Therapeutics, Inc., a developer of targeted molecular therapies for cancer, today reported additional efficacy data from the companys recent regulatory filings seeking approval of ADVEXIN(R) (p53 tumor suppressor therapy) in the United States and Europe. These findings resulted from supportive statistical analyses based on data from the pivotal Phase 3 clinical trial of ADVEXIN in patients with recurrent, refractory head and neck cancer. These analyses (Cox Regression) evaluated the length of survival of patients in the biomarker population receiving ADVEXIN as compared to patients in the biomarker population receiving methotrexate. Results showed that patients with p53 tumor profiles positive for ADVEXIN efficacy demonstrated statistically significant increased survival benefit at both six months (p less than 0.0051) and overall (p = 0.0265) following treatment with ADVEXIN. Additionally, these analyses showed that for patients with tumor p53 profiles...

OncoVista Innovative Therapies to Begin Enrolling Patients in a Phase I/II Study of Cordycepin in Patients with Refractory TdT-Positive Leukemia

noemail@biohouston.org — Tue, 22 Jul 2008 12:00:00 GMT

July 22, 2008 -- OncoVista Innovative Therapies, Inc., a biopharmaceutical company engaged in the development and commercialization of targeted cancer therapies and diagnostics, announced today that patient recruitment has commenced in the companys Phase I/II study of cordycepin for the treatment of patients with terminal deoxynucleotidyl transferase (TdT)-positive refractory leukemia. Participating clinical sites include the Dana Farber Cancer Institute (Boston, MA) and the Cancer Therapy and Research Center (San Antonio, TX). Initiation of this Phase I/II clinical trial of cordycepin is an important milestone for OncoVista. We believe cordycepin will prove to be an effective and well-tolerated treatment option for many leukemia patients who do not respond to other therapies. We are very excited to have the trial up and running. stated Alexander L. Weis, Ph.D., President and Chief Executive Officer of OncoVista Innovative Therapies. OncoVista has received Orphan Drug Designation from...

Opexa Conducts Additional Analysis on Phase I/II Extension Study with Tovaxin for Multiple Sclerosis

noemail@biohouston.org — Tue, 22 Jul 2008 12:00:00 GMT

July 22, 2008 -- Opexa Therapeutics, Inc., a company leading in the development of cell therapies for multiple sclerosis (MS) and diabetes, has completed an internal assessment of data from its Phase I/II two year extension study with Tovaxin in patients with MS. While confirming the favorable safety and efficacy profile of Tovaxin, further analysis also confirms both the benefit of consecutive annual treatments with Tovaxin and the advantage of tailoring each vaccination to the patient’s changing disease profile. The extension study evaluated 22 intent-to-treat patients that had enrolled in two Phase I/II open-label clinical studies with Tovaxin. 13 patients were enrolled with Relapse Remitting Multiple Sclerosis (RRMS) and 9 with Secondary Progressive Multiple Sclerosis (SPMS). After the first annual course of treatment the company conducted an analysis of each patient’s specific disease profile and myelin peptide epitope profile using Opexa’s proprietary Epitope Analysis Assay...

Repros Therapeutics Inc. Announces That Proellex Administered to Patients as Cyclic Therapy to Treat the Symptoms of Uterine Fibroids for Up to 30 Months Shows No Adverse Effects on the Endometrium

noemail@biohouston.org — Wed, 16 Jul 2008 22:45:00 GMT

July 16, 2008 -- Repros Therapeutics Inc. today released strong results from its completed extension safety study of Proellex in the chronic treatment of the symptoms associated with uterine fibroids. To date there have been no abnormal histological findings from the endometrial biopsies taken post menses after cessation of drug administration. As of this release, results from 13 women who had endometrial biopsies post menses following last dose of drug in a two-drug cycle extension study of Proellex in the treatment of symptoms associated with uterine fibroids are available. These women have been exposed to Proellex for one three-month and two four-month drug cycles to help control the symptoms of their uterine fibroids. These three cycles have covered a span of two and one half years which exceeds current FDA guidance for the duration of exposure to hormonal drugs. The biopsies have been read by a panel of three expert pathologists all of whom will remain blinded to the treatment...

Opexa's Phase IIb Study of Tovaxin Receives Positive Review

noemail@biohouston.org — Tue, 08 Jul 2008 12:00:00 GMT

July 8, 2008 -- Opexa Therapeutics, Inc., a company leading in the development of cell therapies for multiple sclerosis announced today that the Data Safety Monitoring Board (DSMB) overseeing the on-going Phase IIb clinical study of Tovaxin has recommended that the trial continue unmodified. This positive recommendation follows a regularly scheduled meeting of the DSMB in June and is based upon an evaluation of clinical, magnetic resonance imaging (MRI) and safety data that had been recorded for all patients to date. The TERMS trial (Tovaxin for Early Relapsing Multiple Sclerosis) is nearing completion and the DSMB has two additional scheduled meetings in July and August of this year. Tovaxin is being evaluated in a multi-center, randomized, double blind, placebo controlled study in 150 patients suffering from Relapse Remitting Multiple Sclerosis (RRMS) or Clinically Isolated Syndrome (CIS). The trial was initiated in the third quarter of 2006 and enrollment was completed in the...

Introgen Reduces Development Staff to Focus on Commercial Activities after ADVEXIN Regulatory Filings in U.S. and Europe

noemail@biohouston.org — Thu, 03 Jul 2008 05:00:00 GMT

July 03, 2008 -- Introgen Therapeutics, Inc. today announced a re-allocation of employees to focus on regulatory review and commercial activities. After years of product development, Introgen is directing corporate spending toward regulatory review programs, commercialization and the future marketing of ADVEXIN therapy. Recently the Company achieved the major corporate milestone of filing for regulatory approval of ADVEXIN cancer therapy in the U.S. and Europe. From its current total of approximately 70 employees, Introgen will eliminate approximately 20 positions primarily associated with ADVEXIN development and regulatory submission programs that have now been completed. Some of the approximately 50 remaining Introgen employees and some new employees are expected to join Introgens manufacturing subsidiary, Introgen Technical Services, Inc. The Company anticipated reductions in ADVEXIN program expenses contained in previous financial guidance. These steps will allow Introgen to...

Fifteen Students Launch Into Space Research Internship

noemail@biohouston.org — Tue, 01 Jul 2008 05:00:00 GMT

July 1, 2008 -- Fifteen students are spending the summer at NASA Johnson Space Center, working alongside space life scientists and space medicine researchers as part of the National Space Biomedical Research Institute’s Summer Internship Program. As the International Space Station nears completion, these young scientists are getting a taste of health and medical research related to living in space for long periods and to sending humans back to the moon. The 10-to-15 week program provides the opportunity for undergraduate, graduate and medical students to join ongoing research activities at NASA. The 2008 NSBRI Summer Interns and their home institutions are: -Teresa Ai, Duke University -Justin Barba, Texas A&M University -Michelle Bruner, Mars Hill College -John Cackler, Stanford University -Pushan Dasgupta, Harvard University -James Fiedler, Iowa State University -Lauren Frost, West Virginia University -Jennifer Hirt, University of Kansas Medical Center -Stephanie...

Introgen Submits ADVEXIN(R) Regulatory Applications in the U.S. and Europe

noemail@biohouston.org — Mon, 30 Jun 2008 13:30:00 GMT

June 30, 2008--Introgen Therapeutics, Inc. submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) requesting marketing approval for ADVEXIN(R) p53 therapy to treat recurrent, refractory head and neck cancer. Simultaneously, Gendux Molecular Limited, an Introgen subsidiary, submitted a Marketing Authorization Application (MAA) to the European Medicines Evaluation Agency (EMEA) for the same indication. ADVEXIN represents the first of a new class of tumor suppressor cancer therapy and is the first of its kind to be submitted for regulatory approval in the United States and Europe. Introgen has requested Priority Review from the FDA for ADVEXIN. Priority Review is typically granted to compounds that provide significant medical benefit compared to existing treatments for a disease. If Priority Review is granted, the FDA will have up to six months from submission date to take action on the dossier. ADVEXIN is considered an Orphan Drug in the US for...

Repros Therapeutics Inc. Initiates a Comparative Phase 2b Study of Oral Androxal as Compared to Topical Testim Examining Effects on Male Fertility and Testicular Function

noemail@biohouston.org — Mon, 30 Jun 2008 10:00:00 GMT

June 30, 2008 -- Repros Therapeutics Inc. reported today that the clinical sites have been initiated for its Phase 2b clinical study monitoring the effects of Repros’ oral drug Androxal® on male fertility and testicular function in patients being treated for low testosterone as compared to Testim®, a popular marketed topical testosterone medication. Enrollment of the 24 patients will commence at two sites in the New York City area shortly. The study is being conducted by Dr. Jed Kaminetsky in New York City and Dr. Michael Werner in Purchase, NY. All subjects will have been previously diagnosed with secondary hypogonadism and treated with topical testosterone for at least 6 months but not more than 2 years. Patients will be instructed to discontinue their topical testosterone use and return to the clinic within 7 to 21 days. If their morning testosterone is less than 300 ng/dl, they will be randomized to either Androxal or Testim. Patients will be treated for 6 months with results...

Opexa Therapeutics Presents Monocyte-Derived Islet Cell Research at the International Society for Stem Cell Research Annual Meeting

noemail@biohouston.org — Mon, 16 Jun 2008 13:00:00 GMT

June 16, 2008 -- Opexa Therapeutics, Inc., a cell therapy development and commercialization company, today announced a recent poster presentation at the 2008 Annual Meeting of the International Society for Stem Cell Research held in Philadelphia June 11 – 14, 2008. The poster, titled Ex vivo differentiation of adult human peripheral blood monocyte-derived cells into functional insulin-producing cells for the treatment of diabetes was presented Friday, June 13th by Glenn Winnier, Ph.D., Director of Stem Cell Research. The presentation described further characterization of the Company’s monocyte-derived islet technology (MDI). Opexa has previously shown that its proprietary monocyte-derived stem cells (MDSCs) can form into islet cell-like clusters that express pancreatic specific markers, including pdx-1, insulin, glucose transporter 2, glucagon and somatostatin as determined by immunocytochemistry. Using gene array technology, upregulation of numerous genes involved in the insulin...

Industrial Postdoctoral Position

Tue, 22 Jul 2008 16:47:28 GMT

Title: Industrial Postdoctoral Position
Description:

Rochal Industries, a small private research company focused on new materials for wound care, is seeking to hire a synthetic polymer chemist (MS or PhD) for a one year Infustrial Postdoctoral position. The successful candidate will prepare novel polymer systems and formulate compositions for wound care applications.

Required Experience: A background in free radical polymerization techniques is required.
This Job Requires the Follow Skills:

Understanding of polymer physical properties and analytical testing procedures.

Send resume with references to Dr. Joseph C Salamone at jcsalamone@yahoo.com

Education Required: MS or PhD
Planned Duration of Employment: Full Time Temporary

Contact info:

Dr. Joseph C. Salamone (Add to Contacts)
(561) 866-0930

Rochal Industries

Clinical Project Manager Clinical Development (CPM 23894)

Thu, 17 Jul 2008 20:36:26 GMT

Title: Clinical Project Manager Clinical Development (CPM 23894) Description: This position will be responsible for overseeing the daily activities of Phase 1-3 world-wide clinical trials of drug candidates by ensuring that high quality and valid data supports regulatory applications and approvals of new-marketed products and indications. Responsibilities will include, but will not be limited to: managing Clinical personnel to conduct investigator identification, selection, training and routine monitoring; maintaining and negotiating vendor contracts; managing budgets and payments; serving as the study lead on Clinical project teams; participating in the design and development of clinical study protocols and CRFs across a range of therapeutic areas to ensure monitoring efforts fully complement the drug development process within established timelines; managing and executing trials through a combination of internal and external (CRO) staff; and other duties as assigned or required. ...

Vice President of Manufacturing

Wed, 16 Jul 2008 22:00:00 GMT

Title: Vice President of Manufacturing Description: Manufacturing Executive (VP) Leader: This position requires a hands-on executive that can design and implement the manufacture of a series of diagnostic medical devices and oversee all phases from project management, outsourced operations, supply-chain, logistics, field services, quality controls as well as being familiar with all necessary regulatory matters. Entrepreneurial: This leader will be the first manufacturing person onboard and the group will form underneath his or her leadership in this two-year old company. This executive must be a self-starter with seasoned experience in knowing from A to Z how to build a highly technical optical imaging product in the most effective and cost-efficient manner. Title: This job reports directly to the Chief Operating Officer and hold the title of Vice President of Manufacturing. Other skills should include the building of a core team of specialists responsible for...

Lab Director - CLIA Certified

Tue, 15 Jul 2008 15:00:00 GMT

Title: Lab Director - CLIA Certified Description: The Laboratory Director is responsible for the overall operation and administration of a high complexity genetic testing CLIA certified laboratory. Must be qualified to be a Laboratory Director by the State of Texas and meet the minimum CLIA requirements for high complexity testing. Tasks and responsibilities: • Provides direction and coordination of the technical and administrative functions for the CLIA Laboratory. • Ensure a Quality Management System (QMS) is developed and implemented, for all phases of testing, to include the pre-analytic, analytic, and post-analytic phases of testing as well as general laboratory systems. • Ensure test systems have established acceptable performance specifications for the performance characteristics of accuracy, precision, analytical sensitivity, and analytical specificity of the system, to include performance, maintenance and calibration of instrumentation and equipment used to perform...

Technology Manager

Wed, 02 Jul 2008 18:38:50 GMT

Title: Technology Manager Description: The University of Texas Medical Branch (UTMB) at Galveston, a leading academic health sciences center located on the Texas Gulf Coast, is searching for a highly motivated and enthusiastic candidate to join our Technology Management Office in the Office of the President. Join an institution with a reputation for advancing health care through education, research and innovation. In addition to UTMB’s more than 12,500 faculty and staff, we are home to more than 2,000 students in the schools of medicine, snursing, allied health sciences and graduate biomedical sciences. The Technology Manager will encourage faculty to disclose inventions resulting from research in order to secure appropriate protections and potential public benefit through commercialization. In addition, incumbent will manage a portfolio of intellectual properties and coordinate all patent activities, including legal requirements and financial and status reporting. Duties also...

Staff Scientist

Mon, 30 Jun 2008 17:23:00 GMT

Title: Staff Scientist Description: Stematix, Inc is a Houston-based start up company whose mission is to bring safe and effective stem cell therapies to more people, faster. We are seeking dedicated, motivated scientists for our Research and Development team who will thrive in an intense start-up environment in the fast-growing area of Adult Stem Cell Therapy. Primary duties include isolation, processing and culture of human primary cells, cell-based assays, and FACS analysis. Other tasks include data analysis, maintenance of lab equipment, and inventory and supply of materials. Will require limited weekend work for culture maintenance. Will report directly to Technical Director. Salary is commensurate with experience. Required Experience: Must hold at least a BS in the Life Sciences, MS preferred, with 4-5 years (for BS), or 2-3 years (for MS) prior experience working in an academic or industry laboratory. Must have prior experience with primary cell culture and sterile...

Global Director of Quality Assurance

Wed, 25 Jun 2008 17:00:00 GMT

Title: Global Director of Quality Assurance Description: Challenging Opportunity in Quality Assurance Looking for a challenging, satisfying position with a growing, dynamic CRO? Pharm-Olam International (‘POI’) is a global full service Contract Research Organization providing clinical solutions to the pharmaceutical and biotechnology industry. Due to expanding business needs, POI has the following vacancy at its global headquarters in Houston. Global Director of Quality Assurance With a minimum of 10 years experience in either a CRO or pharmaceutical environment, the ideal candidate will be responsible for developing and enhancing worldwide clinical quality assurance policies. Monitoring and tracking ongoing studies’ clinical quality assurance compliance with regard to GCPs, SOPs, EU directives, and national and local guideline and laws. The ideal candidate must have extensive knowledge of GCP and be available to travel. POI offers a competitive salary and benefits package,...

Director R&D

Thu, 19 Jun 2008 00:00:00 GMT

Title: Director R&D Description: This individual will have the unique opportunity to utilize their scientific skills in the environment of an innovative life science company. This person will have responsibility in conducting and managing daily experiments and team members that are critical to project deadlines. You will work closely with the Chief Scientific Officer to assist with experimental designs, project execution, meet deadlines, and generate formal reports. Technical applications include basic laboratory techniques with strong emphasis on immunohistochemistry and flow cytometry analysis. This person will be responsible for writing scientific proposals including small business grants. We are looking for someone who is a good team player, meticulously detailed and organized, and has good communication skills. Required Experience: Bachelor’s degree and Doctorate degree in a scientific related discipline Minimum of 5 years research experience in industry or...

Licensing Assistant

Thu, 12 Jun 2008 19:06:30 GMT

Title: Licensing Assistant
Description: Provides research and analysis services to one or more licensing personnel within the Office of Technology Commercialization. Such research and analysis is provided to licensing personnel through reports, databases and other forms of information essential for the successful transfer of the A&M System’s proprietary research results to commercial application through license agreements. Required Experience: Bachelor's degree in engineering, agriculture or life science or equivalent combination of education and experience (eight years experience with high school graduation or four years with an Associate degree).
This Job Requires the Follow Skills:

One year professional technology transfer experience in industry or in technology transfer operation in academia, or laboratory research experience as obtained in completing in an advanced degree in engineering, agriculture or life science. Ability to multi-task and work cooperatively with others.

Education Required: Bachelor's Degree
Planned Duration of Employment: Full Time

Contact info:

Texas A&M University Human Relations (Add to Contacts)
(979) 458-6169

Texas A&M System

Regulatory Submissions Manager (RSM 23165)

Fri, 06 Jun 2008 18:08:29 GMT

Title: Regulatory Submissions Manager (RSM 23165)
Description:

This position is responsible for managing and maintaining existing IND/CTA submissions and preparing amendments and annual reports in compliance with FDA regulations. Responsibilities will include, but will not be limited to: working with CROs for ex-US submissions; coordinating with functional leads in various disciplines to assemble documents including writing, reviewing, editing and publishing submissions; assisting with pre-IND meeting briefing packages and initial IND submissions for new programs; representing the department on multi-disciplinary development sub-teams; mentoring personnel; and other duties as assigned or required.

For Consideration, please send your resume with cover letter, indicating position interest to the contact below.

Required Experience:

Minimum of five years experience in a regulatory position within a biotech, pharmaceutical or clinical research organization
Experience with electronic filing submissions preferred
Excellent organization and communication skills
Ability and desire to work in a team-oriented environment

This Job Requires the Follow Skills:
Education Required: Bachelor’s degree in a scientific discipline
Planned Duration of Employment: Full Time

Contact info:

Human Resources (Add to Contacts)
281-863-8050 (FAX)

Lexicon Pharmaceuticals, Inc.

8800 Technology Forest Place

The Woodlands, TX 77381
US

2008 Annual Luncheon

Wed, 23 Jul 2008 21:19:27 GMT

September 11, 2008 11:30 AM to 1:30 PM Crystal Ballroom at the Rice 909 Texas St. Bringing Research to Life Dr. Elsa Murano President of Texas A&M University Click here to register for this event The upcoming BioHouston annual luncheon, Bringing Research to Life, will feature the new Texas A&M President, Dr. Elsa Murano, as our speaker. Research, particularly in the rapidly expanding life sciences, is the cornerstone in Texas A&M’s quest to become a top-10 public institution by 2020. The impact of this aggressive initiative by the Aggies is far-reaching, as well as critical in expanding the intellectual capital of the state. Dr. Murano began her professorial career in 1990 as an Assistant Professor in the Department of Microbiology, Immunology and Preventative Medicine at Iowa State, the position she held prior to joining the Texas A&M...

Members & Associates

Tue, 22 Jul 2008 14:52:17 GMT

We are grateful to our members and contributors for their generous suppport. All of BioHoustons events and programs are designed to benefit our member institutions and strengthen life science companies in the Houston area. We are happy to report that our membership is growing as more contributors join us to build Houstons life science industry. Many of your colleagues have already joined BioHouston as Members or Associates. We represent more than 120 biotechnology and life science companies, academic institutions, healthcare orgnaizations, service providers and philanthropic organizations in the Houston region. The organization is growing by leaps and bounds as the people of Houston realize the importance of this developing economic engine for the region. We are helping to lead the most innovative and dynamic industry in the world by helping our Members and Associates find continuing success and opportunities. We invite you to join us in helping to create a vibrant life science...

BioHouston Newsletter

Fri, 18 Jul 2008 18:17:40 GMT

BioHouston Newsletter--July 18, 2008 Buy Your Table Now! Dont miss BioHoustons Annual Luncheon on September 11, 2008 with Dr. Elsa Murano, the new president of Texas A&M University. Dr. Murano will discuss her vision on the future of Texas A&M and the Universitys role in shaping the life sciences indusrtry in our region. For more information regarding this event, click here. Sponsorship opportunities available....please contact Keisha Curtis at 713.979.9212 Events & Announcements Why Choose to Attend this Breakfast? The Relationship of Psychology and Neuroscience in the Decisions We Make--August 6--Dr. Montague is the author of a provocative book that explores the psychology and neuroscience behind the decisions we make on a daily basis titled Why Choose This Book-How We Make Decisions--Sponsorship opportunities available...please contact Keisha Curtis at 713-979-9212 Rice Universitys Advances in Tissue Engineering 2008--August 13 - 16--BioHouston members receive...

BioHouston Blog

Fri, 18 Jul 2008 18:10:56 GMT

M. D. Anderson Earns Top Ranking for Cancer Hospitals In Annual U.S. News & World Report Survey July 10, 2008 HOUSTON – The University of Texas M. D. Anderson Cancer Center once again is the top hospital in the nation for cancer care, according to the U.S. News & World Reports annual America’s Best Hospitals survey. This is the fourth time in the past five years that M. D. Anderson has achieved the lead ranking. It has been ranked as one of the top two hospitals for cancer care for 19 years since the survey began. M. D. Anderson specialties earning national rankings also include ear, nose and throat (4); urology (9); and gynecology (16). The U.S. News & World Report rankings are based on a reputation survey of board-certified physicians around the nation, patient data and a mix of care-related factors such as nurse-to-patient ratios, current technologies and services available to patients and the community. The data gathered by U.S. News & World Report complements the wide...

Associate Advisory Board

Thu, 17 Jul 2008 16:32:50 GMT

Ngu Morcho AlphaDev Mark Shumbera Aptamed Paul R. Morico Baker Botts LLP Charles Szalkowski Baker Botts LLP Meg Boulware Baker McKenzie LLP Gray Hancock British Consulate-General Laura Capper CAP Resources Gwen Wagner CenterPoint Energy Steven M. Plumb Clear Financial Solutions, Inc. Michael E. Novelli Cypressbrook Company Dan Watkins, Ph.D. DFJ Mercury Debbie Pennington Economic Development Alliance for Brazoria County Carole Faig Ernst & Young LLP Jim Meador Fairway Medical Technologies John M. Farrell FKP Architects, Inc. Michael Clements Frost Bank Robert Wilson ...

Education & Workforce

Tue, 01 Jul 2008 16:58:57 GMT

Texas in Top 5 Regions in the World for Biotechnology As one of the top 5 regions in the world for biotechnology, the presence of life science careers in Texas is growing, especially in the Houston region. Home to the Texas Medical Center, Houston has the largest medical center in the world and offers a wide range of educational opportunities and careers in the life sciences. Need a job? Click here to search our job board. Looking to fill open positions? Click here. EDUCATION The institutions in the Houston/Galveston offers extensive programs in biodefense and infectious disease, cardiovascular medicine, genetics/genomics, nanotechnology, and oncology. If you are unsure of what path to take in your career in the life sciences, visit H.O.T. Jobs to view position that is best for you. Specific points include: areas of specialization licensure certification educational programs work environment length of tranining professional associations ...

Capital Development

Tue, 01 Jul 2008 16:54:25 GMT

Houston is the home to the largest medical center in the world. With over $1.5 billion in annual academic research investments and over 140 life science companies, the region has attracted venture capitalists from across the nation to invest in the growing life science industry in Houston. Texas has also become a hot spot for venture capital investments as a result of the recent approval of the $3 billion cancer research institute by Governor Rick Perry, which will distribute up to $300 million in annual grants over the next decade. Listed below are resources for biotech firms, ranging from funds to relevant conferences. Texas Emerging Technology Fund Gulf Coast RCIC Match-Making Meetings SBIR/STTR Support for Emerging Companies Venture Capital Firms National Industry Conferences Vanguard Ventures is an early stage venture...

Programs & Events

Tue, 01 Jul 2008 16:53:13 GMT

BioHouston’s activities provide the greatest leverage in making the Houston region a world-class competitor in the life science industry. All of our activities are designed to: CONVENE people and organizations that need to come together to make the life science industry in Houston ignite, including scientists, intellectual property and product development experts, venture capitalists, pharmaceutical companies, and others COMMUNICATE and interact so that people and organizations can learn from one another, share information and explore opportunities CATALYZE the discoveries and commercial development so that the true potential of the life science industry in Houston can be unlocked We are deeply grateful to our many funding partners and members who are helping us fulfill our vision of building the Houston region’s life science industry into a global competitor. EVENTS BioHouston hosts over 60 events each year to nurture the critical elements required for...

Why Join BioHouston?

Tue, 01 Jul 2008 16:52:42 GMT

WHY JOIN BIOHOUSTON? Many of your colleagues have already joined BioHouston as Members or Associates. We represent more than 120 biotechnology and life science companies, academic institutions, healthcare organizations, service providers and philanthropic organizations in the Houston region. The organization is growing quickly as the people of Houston realize the importance of this developing economic engine for the region. We are helping to lead the most innovative and dynamic industry in the world by helping our Members and Associates find continuing success and opportunities. Benefits of joining BioHouston are myriad -- prominent exposure to key people in the industry through more than 80 networking events annually, discounted registration rates to BioHouston events, and much more. For more information, please click here. WHO SHOULD JOIN? All components of the life science industry are encouraged to become members of BioHouston. Our membership ranges from research...

BioHouston Breakfast Forum

Fri, 23 May 2008 17:27:20 GMT

August 6, 2008
7:30 AM - 9:00 AM

M. D. Anderson South Campus Research Building II

7435 Fannin Street

Houston, TX 77054

Why Choose to Attend this Breakfast? The Relationship of Psychology and Neuroscience in the Decisions We Make

Our featured speaker for the August Breakfast Forum is Read Montague, Ph.D., Professor in the Department of Neuroscience at Baylor College of Medicine, Director of the Human Neuroimaging Lab and Director of the Center for Theoretical Neuroscience.

Dr. Montague's work focuses on computational neuroscience - the connection between the physical mechanisms present in real neural tissue and the computational functions that these mechanisms embody.

Dr. Montague is the author of a provocative book that explores the psychology and neuroscience behind the decisions we make on a daily basis, titled Why Choose This Book: How We Make Decisions.

Sponsorship for the August Breakfast Forum available...please contact Keisha Curtis at 713-979-9212.

Strategic Planning Initial Test

noemail@biohouston.org — Wed, 16 Jan 2008 16:00:00 GMT

Objectives: BioHouston will use this data to prepare for the future.

Release Date: 16-Jan-08 10:00 AM
Expiration Date: 15-Apr-08 10:00 AM

Survey Test 1

noemail@biohouston.org — Wed, 16 Jan 2008 16:00:00 GMT

Objectives: This is a test survey

Release Date: 16-Jan-08 10:00 AM
Expiration Date: 15-Apr-08 10:00 AM
Test Survey, please take as you would a regular survey.

Lorem ipsum survey

noemail@biohouston.org — Wed, 10 Oct 2007 22:00:31 GMT

Objectives:

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diem nonummynibh euismod tincidunt ut lacreet dolore magna aliguam erat volutpat. Ut wisis enim ad minim veniam, quis nostrud exerci tution ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis te feugifacilisi.

Duis autem dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisis at vero eros et accumsan et iusto odio dignissim qui blandit praesent luptatum zzril delenit au gue duis dolore te feugat nulla facilisi.

Ut wisi enim ad minim veniam, quis nostrud exerci taion ullamcorper suscipit lobortis nisl ut aliquip ex en commodo consequat. Duis te feugifacilisi per suscipit lobortis nisl ut aliquip ex en commodo consequat.Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diem nonummy nibh euismod tincidunt ut lacreet dolore magna aliguam erat volutpat.

Ut wisis enim ad minim veniam, quis nostrud exerci

Release Date: 10-Oct-07 5:00 PM
Expiration Date: 10-Jan-08 5:00 PM

Ut wisis enim ad minim veniam, quis nostrud exerci

Lorem ipsum

2007-10-10T22:00:31Z

Instructor: Instructor

Lorem ipsum